Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice
High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for obesity. Our findings highlight the need for policies to address cost and could inform discussions between healthcare providers and patients concerning cost and side effects.
Authors
- Michael B. Rothberg (ORCID: https://orcid.org/0000-0002-2063-1876)
- Phuc Le (ORCID: https://orcid.org/0000-0003-4788-773X)
- Jordan M. Alpert (ORCID: https://orcid.org/0000-0002-7066-4748)
- Winfield Scott Butsch (ORCID: https://orcid.org/0000-0001-7137-9423)
- H. Renner
- Hamlet Gasoyan (ORCID: https://orcid.org/0000-0002-1627-9777)
- Rebecca Schulte (ORCID: https://orcid.org/0000-0002-0009-8947)
- Nicholas J. Casacchia (ORCID: https://orcid.org/0000-0003-2291-835X)
- Victoria Criswell
- Jacqueline Fox
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- University School (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Obesity
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1002/oby.70058
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.06
Funders
- Cleveland Clinic